Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes analysis with 18F-fluorodeoxyglucose positron emission tomography

Circulation: Cardiovascular Imaging

Volumn 3, Issue 2, 2010, Pages 142-148

  Kim, Tae Nyun ^a   Kim, Sungeun ^a   Yang, Sae Jeong ^a   Yoo, Hye Jin ^a   Seo, Ji A ^a   Kim, Sin Gon ^a   Kim, Nan Hee ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Choi, Kyung Mook ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Impaired glucose tolerance; Inflammation; Positron emission tomography; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; B SCAN; BODY MASS; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; VASCULITIS; ANALYSIS OF VARIANCE; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GLUCOSE INTOLERANCE; INFLAMMATION; INTIMA; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; SCINTISCANNING; TUNICA MEDIA;

ADIPONECTIN; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TUNICA INTIMA; TUNICA MEDIA;

EID: 77951883237     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.109.888909     Document Type: Article

References (39)

1. Niskanen L, Turpeinen A, Penttila I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998; 21: 1861-1869.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
3. Pickup JC. Inflammatory markers and type 2 diabetes. Diabetes Technol Ther. 2006; 8: 1-6.
4. Uusitupa M, Siitonen O, Aro A, Pyorala K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1985; 28: 22-27.
5. Standards of medical care in diabetes-2009. Diabetes Care. 2009; 32 (Suppl 1) : S13-S61.
6. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care. 1999; 22: 233-240.
7. van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000; 20: 2408-2413.
8. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol. 1998; 32: 655-662.
9. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004; 45: 1816-1821.
10. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. (18) F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004; 45: 1245-1250.
11. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006; 48: 1818-1824.
12. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006; 48: 1825-1831.
13. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007; 49: 1533-1539.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005; 28 (Suppl 1) : S37-S42.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: executive summary. Cardiol Rev. 2005; 13: 322-327.
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hun-ninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44: 720-732.
19. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999; 100: 1481-1492.
20. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, Nawata H. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006; 19: 1206-1212.
21. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007; 48: 471-480.
22. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008; 49: 871-878.
23. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
24. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007; 49: 2129-2138.
25. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995; 36: 1301-1306.
26. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-2711.
27. Tahara N, Kai H, Nakaura H, Mizoguchi M, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007; 28: 2243-2248.
28. Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R. Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. Diabetes Care. 2002; 25: 1308-1312.
29. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128: 262-269.
30. Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med. 2006; 23: 609-616.
31. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke. 2005; 36: 2764-2772.
32. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, nonin-vasive magnetic resonance imaging. Circulation. 2001; 104: 249-252.
33. Goldberg IJ. Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001; 86: 965-971.
34. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004; 95: 764-772.
35. Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL. Predominance of a proinflammatory phenotype in monocyte-derived macro-phages from subjects with low plasma HDL-cholesterol. Arterioscler Thromb Vasc Biol. 2007; 27: 1115-1122.
36. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009; 6: 27-35.
37. Goldstein BJ, Scalia R. Adipokines and vascular disease in diabetes. Curr Diab Rep. 2007; 7: 25-33.
38. Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, Kumar R, Alavi A. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008; 35: 562-569.
39. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999; 341: 248-257.